3 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | — | -$63M | — | — | -$52M | $17M | $176M |
| 2024 | — | -$61M | — | — | -$49M | $10M | $168M |
| 2023 | — | -$36M | — | — | -$34M | $10M | $83M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$26M | — | — | -$28M | $16M | $264M |
| Dec '25 | — | -$16M | — | — | -$12M | $17M | $176M |
| Sep '25 | — | -$14M | — | — | -$10M | $20M | $138M |
| Jun '25 | — | -$18M | — | — | -$14M | $20M | $148M |
| Mar '25 | — | -$15M | — | — | -$17M | $20M | $161M |
| Dec '24 | — | -$15M | — | — | -$14M | $10M | $168M |
| Sep '24 | — | -$17M | — | — | -$13M | $10M | $182M |
| Jun '24 | — | -$16M | — | — | -$12M | $10M | $193M |
| Mar '24 | — | -$13M | — | — | -$11M | $10M | $206M |
| Dec '23 | — | -$11M | — | — | -$12M | $10M | $83M |
| Sep '23 | — | -$9M | — | — | -$8M | — | — |
| Jun '23 | — | -$9M | — | — | -$7M | — | — |
| Mar '23 | — | -$7M | — | — | -$8M | — | — |
See the revenue and net-income charts above for Alto Neuroscience, Inc.'s multi-year trend.
As of FY2025, Alto Neuroscience, Inc. reported $17M of total debt against $176M of cash; operating income covered interest expense -26.9×.
In FY2025, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.